World ADC London 2020

Now in its 10th year, World ADC London prides itself in being the industry-leading conference to help forward-thinking researchers from the pharmaceutical, biotech and academic community advance the development of antibody-drug conjugates.

Bringing together the latest ADC science, clinical data and lessons learned to enable drug developers to maximise the clinical therapeutic window of your ADC.

As Europe’s largest gathering of ADC stakeholders, seize the opportunity to network with 320 drug developers from 160 active ADC organisations. You’ll be able to build new connections, further cement partnerships and catch up with peers.

What’s new for this Year?
* A Fourth Stream. To delve deeper into the ‘biology’ side of ADCs, we’ll be splitting the discovery stream into two – biology and chemistry. This will focus on novel format ADCs, antibody engineering and novel targets, allowing more dedicated time to focus on payload and linkers, in particular, novel payloads.
* The inaugural CMC Day – After the huge success of this seminar at World ADC San Diego, we are excited to bring it to Europe. Focussed from Phase II through to commercial-scale manufacturing, the inaugural CMC Seminar Day will enable you to effectively scale up your manufacturing operation. With presentations delving into formulation and fill-finish challenges, gain exclusive insights for overcoming manufacturing roadblocks and analytical lessons learned.

World ADC Europe is the definitive forum to exchange novel ideas, gather lessons learned and develop new partnerships to power the next 12 months of your ADC research. We’ll connect you with like-minded individuals who share tremendous enthusiasm for all that this therapeutic approach has to offer.

Join the likes of AstraZeneca, Sanofi and Bayer in 2020 at Europe’s longest-standing and most comprehensive ADC conference to power the development of your ADC pipeline.

Speakers: Alain Beck, Pierre Fabre, Alexie Karpov, Novartis, Andrea Gonzalez-Munoz, AstraZeneca, Ashutosh Pathak, Ascentage Pharma, Balakumar Vijayakrishnan, AZ/Spirogen, Barbara Akla, Pierre Fabre, Bart de Goeij, Genmab, Brian O’Mara, Ambrx, Charles Skarbek, Paris Sud, Christopher A. Alabi, Cornell University, Daejin Abidoye, Seattle Genetics, Dan Custar, Mersana, Daniel Shweizer, Novartis, David Bramhill, Bramhill Consulting, Deya Gonzalez, University of Swansea, Ed Ha, AngieX, Eric Lacoste, Sanofi, Gavin Bennett, Bicycle Therapeutics, Giorgio Salciarini, BSP Pharmaceuticals, Gordon Rigg, Independent Consultant, Guy De Roo, Synthon, Hans Georg Lerchen, Bayer, Hillary Schuessler, GSK, Iontcho Vlahov, Endocyte, Jack Wang, Johnson and Johnson, Jacopo Millull, Philogen, Jagath Reddy Junutula, Modmab Therapeutics, Jamie Baker, University College London, James Jim Christie, AstraZeneca, Jens Lorhmann, Novartis, Jeremy Parker, AstraZeneca, John Babcook, Zymeworks, John Harlan, AbbVie, Julian Andreev, Regeneron, Julie Desrivot Guenelle, Pierre Fabre, Justin Mason Holme, HPAPI Project Services Limited, Justin Sweeley, Novasep, Keiji Furuuchi, Eisai, Letrishka Anthony, Beacon Targeted Therapies, Lisa McDermott, Merck, Luc Desnoyers Alain Beck, CytomX, Mark Frigerio, Abzena, Markus Eser, Bayer, Martin Axon, Safebridge, Naresh Jain, NJ Biopharmaceuticals LLC, Paul Hogg, ADC Therapeutics, Phil Howard, Spirogen, Prathap Kumar Mahalingaiah, AbbVie, Rakesh Dixit, BioNavigen, Rich Reynolds, Seattle Genetics, Rick Powers, Independent Consultant, Robert Sussman, Safebridge Consultants, Sam Cazzamali, Philogen, Sibylle Heidelberger, Sciex, Simon Chivers, Independent Consultant, Steffan Woell, Merck, Steve Conlan, University of Swansea, Subhash Chauhan, University of Tennessee, Thomas Pillow, Genentech, Thorsten Sperber, Immunomedics, Trevor Hallam, Sutro Bio, Ulf Grawunder, NBE Therapeutics

Others Details

Time: 8:00 am - 5:00 pm Brochure: https://go.evvnt.com/544071-2?pid=6581